Status:
COMPLETED
Pupil Dilation for Treatment of IFIS
Lead Sponsor:
Denver Health and Hospital Authority
Conditions:
Intraoperative Floppy Iris Syndrome
Eligibility:
All Genders
18-100 years
Phase:
PHASE2
Brief Summary
A novel intervention for targeting the treatment of Intraoperative Floppy Iris Syndrome.
Detailed Description
This study explores the effects that medication can have on increasing pupil dilation. Pupil dilation size is important for operative eye procedures. Decreased pupil size is related to increased compl...
Eligibility Criteria
Inclusion
- 1\. Adults (18 years old or greater) 3. History of having taken, or currently taking any systemic alpha blocker 2. Ability to consent themselves 3. Ability to apply eye drops themselves TID for 7 days
Exclusion
- Subjects with untreated hypertension or baseline BP \>160
- Subjects with Thyrotoxicosis
- Pregnant women or women trying to conceive
- Prisoners
- Inability consent
- Subjects with anatomical narrow angles or who have never had a dilated eye exam
- Subjects currently prescribed brimonidine tartrate for glaucoma
- Subjects who take topical or systemic alpha agonists
- Patients who take monoamine oxidase (MAO) inhibitors
- Patients with known severe cardiovascular disease
Key Trial Info
Start Date :
January 4 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 25 2020
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT03760185
Start Date
January 4 2019
End Date
September 25 2020
Last Update
April 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Denver Health
Denver, Colorado, United States, 80204